Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Cisplatin in Metastatic TNBC
NCT01928680Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Nov 2012
- Primary completion
- Oct 2015
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin, capecitabine in triple-negative breast cancer (TNBC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
cisplatincapecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01928680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01928680.